Please do not interpret today's list as a buy list. I do not advise buying into a dicey market.

OHRP is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Since 12/20 the stock gained 19.32%.